Daniele Focosi to Humans
This is a "connection" page, showing publications Daniele Focosi has written about Humans.
Connection Strength
0.190
-
Molecular validation of pathogen-reduction technologies using rolling-circle amplification coupled with real-time PCR for torquetenovirus DNA quantification. Transfus Med. 2021 Oct; 31(5):371-376.
Score: 0.008
-
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
Score: 0.008
-
COVID-19 infodemics: the role of mainstream and social media. Clin Microbiol Infect. 2021 Nov; 27(11):1568-1569.
Score: 0.008
-
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
Score: 0.008
-
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. Emerg Infect Dis. 2021 Oct; 27(10):2728-2731.
Score: 0.008
-
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
Score: 0.008
-
ABO Blood Group Correlations with Covid-19: Cohort Choice Makes A Difference. Clin Infect Dis. 2021 06 01; 72(11):e919.
Score: 0.008
-
Is a single COVID-19 vaccine dose enough in convalescents ? Hum Vaccin Immunother. 2021 Sep 02; 17(9):2959-2961.
Score: 0.008
-
Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol. 2021 Jul; 107(1):24-28.
Score: 0.008
-
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
Score: 0.008
-
COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. 2021 10; 116(9):935-942.
Score: 0.008
-
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 11; 31(6):e2231.
Score: 0.007
-
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol. 2021 May; 28(2):132-134.
Score: 0.007
-
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. Transfus Apher Sci. 2021 Jun; 60(3):103071.
Score: 0.007
-
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 05; 87(5):2186-2188.
Score: 0.007
-
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. Int J Infect Dis. 2021 Jan; 102:244-246.
Score: 0.007
-
What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Clin Microbiol Infect. 2021 Feb; 27(2):163-165.
Score: 0.007
-
Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2021 03; 31(2):e2170.
Score: 0.007
-
Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 09 16; 33(4).
Score: 0.007
-
Anti-A isohaemagglutinin titres and SARS-CoV-2 neutralization: implications for children and convalescent plasma selection. Br J Haematol. 2020 08; 190(3):e148-e150.
Score: 0.007
-
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
Score: 0.007
-
CDC crossmatch and C1qSCREEN in liver transplantation. Transplantation. 2014 May 27; 97(10):e61.
Score: 0.005
-
Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. Hematol Oncol. 2007 Jun; 25(2):96-7.
Score: 0.003
-
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerg Microbes Infect. 2021 Dec; 10(1):710-712.
Score: 0.002
-
Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution. Emerg Microbes Infect. 2021 Dec; 10(1):1254-1256.
Score: 0.002
-
Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. J Med Virol. 2021 Dec; 93(12):6460-6461.
Score: 0.002
-
Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses. 2021 07 31; 13(8).
Score: 0.002
-
SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. J Med Virol. 2021 Sep; 93(9):5648-5649.
Score: 0.002
-
Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy. Emerg Infect Dis. 2021 04; 27(4):1249-1251.
Score: 0.002
-
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020 08; 43(8):699-709.
Score: 0.002
-
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020 06 11; 24(1):331.
Score: 0.002
-
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. J Med Virol. 2022 02; 94(2):491-498.
Score: 0.002
-
Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects. New Microbiol. 2019 Apr; 42(2):118-120.
Score: 0.002
-
Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Med Microbiol Immunol. 2019 Apr; 208(2):253-258.
Score: 0.002
-
Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. J Med Virol. 2018 09; 90(9):1438-1443.
Score: 0.002
-
The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2018 02; 53(2):180-187.
Score: 0.001
-
Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. J Clin Virol. 2017 09; 94:22-28.
Score: 0.001
-
Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumour Biol. 2017 May; 39(5):1010428317699797.
Score: 0.001